C Unterbuchner1, K Ehehalt2, B Graf2. 1. Klinik für Anästhesiologie, Universitätsklinikum Regensburg, Universität Regensburg, Franz-Josef-Strauss-Allee 11, 93053, Regensburg, Deutschland. Christoph.unterbuchner@ukr.de. 2. Klinik für Anästhesiologie, Universitätsklinikum Regensburg, Universität Regensburg, Franz-Josef-Strauss-Allee 11, 93053, Regensburg, Deutschland.
Abstract
BACKGROUND: Postoperative residual neuromuscular block (train of four ratio <0.9) is an outcome-relevant problem in balanced anesthesia, which increases postoperative morbidity and mortality. Implementation of medium and short-acting muscle relaxants, quantitative neuromuscular monitoring and pharmacological reversal of muscle relaxation reduce the incidence of residual neuromuscular block. The question arises whether this is suitable to create a pragmatic algorithm integrating these three individual methods to reduce paralysis-associated complications? METHODS: A selective literature search was carried out in PubMed and guidelines of national specialist societies were searched using special terms. RESULTS: The incidence of residual neuromuscular block varied among the studies but was as high as 93%. Using calibrated acceleromyography it is possible to identify a residual relaxation with a negative predictive value of 97% (95% confidence interval, CI 83-100%). Reversal by administration of the acetylcholinesterase inhibitor neostigmine reduces the incidence of residual neuromuscular block to 15.4%, in combination with calibrated acceleromyography to 3.3%. Reversal with sugammadex can nearly completely eliminate residual neuromuscular block. Quantitative neuromuscular monitoring and pharmacological reversal can be suitably integrated into a stage-based, pragmatic treatment algorithm. CONCLUSION: The algorithm-based concept of quantitative neuromuscular monitoring and pharmacological reversal using neostigmine and sugammadex enables residual neuromuscular block to be treated within 10 min before extubation of the patient. Ongoing educational programs are essential for implementation of modern muscle relaxant management concepts. Quantitative neuromuscular monitoring should be mandatory for all patients receiving neuromuscular blocking drugs. It would be desirable that German-speaking societies for anesthesiology make appropriate recommendations in guidelines.
BACKGROUND: Postoperative residual neuromuscular block (train of four ratio <0.9) is an outcome-relevant problem in balanced anesthesia, which increases postoperative morbidity and mortality. Implementation of medium and short-acting muscle relaxants, quantitative neuromuscular monitoring and pharmacological reversal of muscle relaxation reduce the incidence of residual neuromuscular block. The question arises whether this is suitable to create a pragmatic algorithm integrating these three individual methods to reduce paralysis-associated complications? METHODS: A selective literature search was carried out in PubMed and guidelines of national specialist societies were searched using special terms. RESULTS: The incidence of residual neuromuscular block varied among the studies but was as high as 93%. Using calibrated acceleromyography it is possible to identify a residual relaxation with a negative predictive value of 97% (95% confidence interval, CI 83-100%). Reversal by administration of the acetylcholinesterase inhibitor neostigmine reduces the incidence of residual neuromuscular block to 15.4%, in combination with calibrated acceleromyography to 3.3%. Reversal with sugammadex can nearly completely eliminate residual neuromuscular block. Quantitative neuromuscular monitoring and pharmacological reversal can be suitably integrated into a stage-based, pragmatic treatment algorithm. CONCLUSION: The algorithm-based concept of quantitative neuromuscular monitoring and pharmacological reversal using neostigmine and sugammadex enables residual neuromuscular block to be treated within 10 min before extubation of the patient. Ongoing educational programs are essential for implementation of modern muscle relaxant management concepts. Quantitative neuromuscular monitoring should be mandatory for all patients receiving neuromuscular blocking drugs. It would be desirable that German-speaking societies for anesthesiology make appropriate recommendations in guidelines.
Authors: Louis-Philippe Fortier; Dolores McKeen; Kim Turner; Étienne de Médicis; Brian Warriner; Philip M Jones; Alan Chaput; Jean-François Pouliot; André Galarneau Journal: Anesth Analg Date: 2015-08 Impact factor: 5.108
Authors: B Brueckmann; N Sasaki; P Grobara; M K Li; T Woo; J de Bie; M Maktabi; J Lee; J Kwo; R Pino; A S Sabouri; F McGovern; A K Staehr-Rye; M Eikermann Journal: Br J Anaesth Date: 2015-05-02 Impact factor: 9.166
Authors: Thomas Fuchs-Buder; Claude Meistelman; François Alla; Arnaud Grandjean; Yann Wuthrich; François Donati Journal: Anesthesiology Date: 2010-01 Impact factor: 7.892
Authors: Daniel Dirkmann; Martin W Britten; Henning Pauling; Juliane Weidle; Lothar Volbracht; Klaus Görlinger; Jürgen Peters Journal: Anesthesiology Date: 2016-06 Impact factor: 7.892
Authors: Catherine M Bulka; Maxim A Terekhov; Barbara J Martin; Roger R Dmochowski; Rachel M Hayes; Jesse M Ehrenfeld Journal: Anesthesiology Date: 2016-10 Impact factor: 7.892
Authors: Chingmuh Lee; Jonathan S Jahr; Keith A Candiotti; Brian Warriner; Mark H Zornow; Mohamed Naguib Journal: Anesthesiology Date: 2009-05 Impact factor: 7.892